Reuters reported that Tracy Beth Høeg, the FDA’s Center for Drug Evaluation and Research (CDER) chief, is expected to leave the agency following Commissioner Marty Makary’s resignation. Høeg became acting CDER director after Richard Pazdur’s earlier departure, and the report suggests the leadership turnover could further increase uncertainty for ongoing drug reviews and day-to-day regulatory work.